Tier 2 — strong

Oral administration of glycine in the prevention of restenosis after coronary angioplasty. A double blind placebo controlled randomized feasibility trial evaluating safety and efficacy of glycine in the prevention of restenosis after angioplasty

Khan M, Ron Van Der Wieken L, Riezebos RK, Tijssen JG, Kiemeneij F, Slagboom T, Laarman GJ
Acute cardiac care 2006 8(1):58-64

Bibliography

PubMed
PMID 16720430
DOI
10.1080/14628840600643383
Funding
Funding was not specified in the indexed abstract; the full funding disclosure has not been verified.
Competing interests
The accessible abstract does not establish the authors' competing interests; absence of a statement is not evidence of no conflicts.

Study snapshot

DesignRandomized controlled human intervention
ModelAdult humans
Sample214 elective-PCI patients randomized in the original indexed report
InterventionChronic oral glycine versus placebo; exact dose not reliably stated in the accessible abstract
Duration6 months
EndpointsAngiographic restenosis; Major adverse cardiac events; Tolerability

What the study showed, in plain terms

In a randomized feasibility trial after coronary angioplasty, glycine was feasible to administer but did not significantly reduce restenosis. Safety observations in this setting cannot establish unlimited long-term safety.

Key findings

  • Restenosis was 17.5% with glycine versus 20.2% with placebo; P=0.82.
  • Adverse effects and major cardiac events did not significantly differ.

What this study can and cannot tell us

Feasibility study in a procedural population, not general cardiovascular prevention.

Exact dose and formulation could not be established from the indexed abstract; the complete original methods are required for regimen details.

Related papers in the corpus

Tier 4
Plasma Glycine and Risk of Acute Myocardial Infarction in Patients With Suspected Stable Angina Pectoris
Ding Y et al. · Journal of the American Heart Association · 2015
Tier 3
Exploring the Role of Glycine Metabolism in Coronary Artery Disease: Insights from Human Genetics and Mouse Models
Biswas S et al. · Nutrients · 2025
Tier 4
Assessing the causal association of glycine with risk of cardio-metabolic diseases
Wittemans LBL et al. · Nature communications · 2019
Tier 4
Genetic Determinants of Circulating Glycine Levels and Risk of Coronary Artery Disease
Jia Q et al. · Journal of the American Heart Association · 2019
Tier 4
The association of genetically determined serum glycine with cardiovascular risk in East Asians
Chang X et al. · Nutrition, metabolism, and cardiovascular diseases : NMCD · 2021
Tier 4
Interplay Between Plasma Glycine and Branched-Chain Amino Acids Contributes to the Development of Hypertension and Coronary Heart Disease
Dziedzic M et al. · Hypertension (Dallas, Tex. : 1979) · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction